Navigation Links
Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference

SAN DIEGO, May 19, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Citi Investment Research Global Healthcare Conference in New York on Wednesday, May 26, 2010 at 3:00 p.m. ET / 12:00 p.m. PT. Alex Casdin, vice president, finance at Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast live through the "Investors" section of Amylin's corporate Web site at, and a recording will be made available on the Web site following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
4. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
5. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
6. Amylin Pharmaceuticals to Webcast Second Quarter Results
7. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
8. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
9. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
10. Amylin Announces Preliminary Tabulation of Annual Meeting Results
11. Amylin Responds to Eastbourne Letter
Post Your Comments:
(Date:12/1/2015)... 1, 2015 ... "2016 U.K. Virology and Bacteriology Testing Market: ... Tests, Supplier Shares by Test, Innovative Technologies, ... offering.  --> ) has ... Virology and Bacteriology Testing Market: Sales and ...
(Date:11/30/2015)... Dec. 1, 2015  An interventional radiology technique shows promise ... preliminary results of a study being presented today at the ... America (RSNA). --> ... decades by interventional radiologists as a way to stop bleeding ... as a means of treating obesity is new. ...
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" ... Norman C.W. Wong to its Board of Directors ... to Zenith with a wealth of experience as co-founder of ... biology. --> --> Dr. ... Epigenetics, board of directors. Zenith,s long standing expertise in epigenetics ...
(Date:11/30/2015)... 2015 TapImmune, Inc. (TPIV), ... innovative peptide and gene-based immunotherapeutics and vaccines for the ... will be presenting at the 8 th Annual ... 2.30 PM PT. Dr. John N. Bonfiglio ... giving the presentation and will join TapImmune management in ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/17/2015)... Paris , qui s,est tenu ... Paris , qui s,est tenu du 17 au ... l,innovation biométrique, a inventé le premier scanner couplé, qui ... même surface de balayage. Jusqu,ici, deux scanners étaient nécessaires, ... digitales. Désormais, un seul scanner est en mesure de ...
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
Breaking Biology News(10 mins):